||
CL-387785 (EKI-785) is an irreversible, and selective EGFR inhibitor with IC50 of 370 pM.
CL-387785 blocks EGF-stimulated autoposphorylation of the receptor in cells (IC50, 5 nM), In cell lines that overexpress EGF-R or c-erbB-2, CL-387785 inhibits cell proliferation (IC50, 31 nM) primarily in a cytostatic manner. [1]
In nude mice overexpressed EGF-R, CL-387785 (80 mg/kg/day, p.o.) profoundly blocks the growth of tumor. [1]In murine models of autosomal recessive polycystic kidney disease (ARPKD), treatment of Balb/c-bpk/bpk (BPK) mice with CL-387785 (90 mg/kg, i.p.) results in a marked reduction of collecting tubule cystic lesions, improved renal function, decreased biliary epithelial abnormalities, and prolonged life span. [2] Doses of CL-387785 as low as 25 mg/kg reduces the growth of HCA-7-induced xenograft tumor, and a dose of 100 mg/kg prevents tumor growth entirely. Dose of 50 mg/kg CL-387785 is effective at reducing the growth of HCT-116-induced xenograft tumor. [5]
References
[1] Discafani CM, et al. Biochem Pharmacol. 1999, 57(8), 917-925.
[2] William E, et al. Kidney International. 2000, 57(1), 33-40.
[3] Hama T, et al. Clin Exp Metastasis. 2012, 29(1), 19-25.
[4] Kancha RK, et al. PloS ONE. 2011, 6(10), e26760.
[5] Roberts RB, et al. Proc Natl Acad Sci. 2002, 99(3), 1521-1526.
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-10-8 05:52
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社